{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:12:56Z","timestamp":1794363176233,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02109-3","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:35:31Z","timestamp":1766572531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4\/6 inhibitors"],"prefix":"10.1186","volume":"27","author":[{"given":"Justine","family":"Dutheil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Boisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Justine","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Chaigneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erion","family":"Dobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Viot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Meynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Goujon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Dalens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Dubourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meneveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Adot\u00e9vi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lia","family":"Meurisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Curtit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2109_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10549-007-9527-6","volume":"105","author":"HT Mouridsen","year":"2007","unstructured":"Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat. 2007;105:19\u201329.","journal-title":"Breast Cancer Res Treat"},{"key":"2109_CR2","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","volume":"18","author":"J Bonneterre","year":"2000","unstructured":"Bonneterre J, et al. Anastrozole versus Tamoxifen as First-Line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol. 2000;18:3748\u201357.","journal-title":"J Clin Oncol"},{"key":"2109_CR3","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","volume":"18","author":"JM Nabholtz","year":"2000","unstructured":"Nabholtz JM, et al. Anastrozole is superior to Tamoxifen as First-Line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol. 2000;18:3758\u201367.","journal-title":"J Clin Oncol"},{"key":"2109_CR4","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","volume":"26","author":"RJ Paridaens","year":"2008","unstructured":"Paridaens RJ, et al. Phase III study comparing exemestane with Tamoxifen as First-Line hormonal treatment of metastatic breast cancer in postmenopausal women: the European organisation for research and treatment of cancer breast cancer cooperative group. J Clin Oncol. 2008;26:4883\u201390.","journal-title":"J Clin Oncol"},{"key":"2109_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1023\/A:1005758127114","volume":"42","author":"JT Kuss","year":"1997","unstructured":"Kuss JT, Muss HB, Hoen H, Case LD. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont oncology association (POA) trials. Breast Cancer Res Treat. 1997;42:265\u201374.","journal-title":"Breast Cancer Res Treat"},{"key":"2109_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ctrv.2013.03.004","volume":"39","author":"M Al-Mubarak","year":"2013","unstructured":"Al-Mubarak M, et al. Fulvestrant for advanced breast cancer: A meta-analysis. Cancer Treat Rev. 2013;39:753\u20138.","journal-title":"Cancer Treat Rev"},{"key":"2109_CR7","unstructured":"Depaquis A. Les inhibiteurs de mTOR: int\u00e9r\u00eat et d\u00e9veloppement en canc\u00e9rologie."},{"key":"2109_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, et al. Everolimus in postmenopausal Hormone-Receptor\u2013Positive advanced breast cancer. N Engl J Med. 2012;366:520\u20139.","journal-title":"N Engl J Med"},{"key":"2109_CR9","unstructured":"Haute autorit\u00e9 de Sant\u00e9. Comission de Transparence de la haute Autorit\u00e9 de sant\u00e9 concernant l\u2019Erivedge (Vismodegib). (2013)."},{"key":"2109_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.clbc.2013.08.011","volume":"13","author":"KI Pritchard","year":"2013","unstructured":"Pritchard KI, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-Negative, hormone Receptor\u2013Positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013;13:421\u2013e4328.","journal-title":"Clin Breast Cancer"},{"key":"2109_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","volume":"34","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor\u2013Positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2016;34:419\u201326.","journal-title":"J Clin Oncol"},{"key":"2109_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/bjc.2017.25","volume":"116","author":"ME Moynahan","year":"2017","unstructured":"Moynahan ME, et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2\u2009\u2013\u2009advanced breast cancer: results from BOLERO-2. Br J Cancer. 2017;116:726\u201330.","journal-title":"Br J Cancer"},{"key":"2109_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1634\/theoncologist.2018-0407","volume":"24","author":"A Prat","year":"2019","unstructured":"Prat A, et al. Everolimus plus exemestane for hormone Receptor-Positive advanced breast cancer: A PAM50 intrinsic subtype analysis of BOLERO\u20102. Oncologist. 2019;24:893\u2013900.","journal-title":"Oncologist"},{"key":"2109_CR14","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"2109_CR15","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013Positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372.","journal-title":"J Clin Oncol"},{"key":"2109_CR16","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346.","journal-title":"J Clin Oncol"},{"key":"2109_CR17","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942\u201350.","journal-title":"N Engl J Med"},{"key":"2109_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","volume":"28","author":"Y-S Lu","year":"2022","unstructured":"Lu Y-S, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in Pre- and perimenopausal patients with HR+\/HER2\u2009\u2013\u2009Advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial. Clin Cancer Res. 2022;28:851\u20139.","journal-title":"Clin Cancer Res"},{"key":"2109_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2020","unstructured":"Sledge GW, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone Receptor\u2013Positive, ERBB2-Negative breast cancer that progressed on endocrine Therapy\u2014MONARCH 2: A randomized clinical trial. JAMA Oncol. 2020;6:116.","journal-title":"JAMA Oncol"},{"key":"2109_CR20","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349.","journal-title":"Ann Oncol"},{"key":"2109_CR21","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1186\/s12885-018-4978-1","volume":"18","author":"A van Ommen-Nijhof","year":"2018","unstructured":"van Ommen-Nijhof A, et al. Selecting the optimal position of CDK4\/6 inhibitors in hormone receptor-positive advanced breast cancer \u2013 the SONIA study: study protocol for a randomized controlled trial. BMC Cancer. 2018;18:1146.","journal-title":"BMC Cancer"},{"key":"2109_CR22","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","volume":"125","author":"D Dustin","year":"2019","unstructured":"Dustin D, Gu G, Fuqua SA. ESR1 mutations in breast cancer. Cancer. 2019;125:3714\u201328.","journal-title":"Cancer"},{"key":"2109_CR23","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard F-C, et al. Elacestrant (oral selective Estrogen receptor degrader) versus standard endocrine therapy for Estrogen receptor\u2013Positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246\u201356.","journal-title":"J Clin Oncol"},{"key":"2109_CR24","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, et al. Endocrine treatment and targeted therapy for hormone receptor\u2013Positive, human epidermal growth factor receptor 2\u2013Negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39:3959\u201377.","journal-title":"J Clin Oncol"},{"key":"2109_CR25","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.3390\/cancers14215206","volume":"14","author":"R Ozyurt","year":"2022","unstructured":"Ozyurt R, Ozpolat B. Molecular mechanisms of Anti-Estrogen therapy resistance and novel targeted therapies. Cancers. 2022;14:5206.","journal-title":"Cancers"},{"key":"2109_CR26","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00432-013-1518-x","volume":"139","author":"N Maass","year":"2013","unstructured":"Maass N, et al. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol. 2013;139:2047\u201356.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2109_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"2109_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"key":"2109_CR29","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, et al. Alpelisib for PIK3CA -Mutated, hormone Receptor\u2013Positive advanced breast cancer. N Engl J Med. 2019;380:1929\u201340.","journal-title":"N Engl J Med"},{"key":"2109_CR30","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, et al. Capivasertib in hormone Receptor\u2013Positive advanced breast cancer. N Engl J Med. 2023;388:2058\u201370.","journal-title":"N Engl J Med"},{"key":"2109_CR31","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on Cyclin-Dependent kinase 4\/6 Inhibition in hormone receptor-Positive, human epidermal growth factor receptor 2-Negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:4004\u201313.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2109_CR32","doi-asserted-by":"publisher","unstructured":"Kalinsky K, et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postmonarch trial. J Clin Oncol Off J Am Soc Clin Oncol. 2024;JCO2402086. https:\/\/doi.org\/10.1200\/JCO-24-02086.","DOI":"10.1200\/JCO-24-02086"},{"key":"2109_CR33","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41388-024-02986-6","volume":"43","author":"A Vasseur","year":"2024","unstructured":"Vasseur A, et al. Fulvestrant and everolimus efficacy after CDK4\/6 inhibitor: a prospective study with Circulating tumor DNA analysis. Oncogene. 2024;43:1214\u201322.","journal-title":"Oncogene"},{"key":"2109_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.clbc.2021.10.002","volume":"22","author":"H Mo","year":"2022","unstructured":"Mo H, et al. Real-World outcomes of everolimus and exemestane for the treatment of metastatic hormone Receptor-Positive breast cancer in patients previously treated with CDK4\/6 inhibitors. Clin Breast Cancer. 2022;22:143\u20138.","journal-title":"Clin Breast Cancer"},{"key":"2109_CR35","doi-asserted-by":"publisher","first-page":"117822342094486","DOI":"10.1177\/1178223420944864","volume":"14","author":"A Dhakal","year":"2020","unstructured":"Dhakal A, et al. Outcome of Everolimus-Based therapy in Hormone-Receptor-Positive metastatic breast cancer patients after progression on Palbociclib. Breast Cancer Basic Clin Res. 2020;14:1178223420944864.","journal-title":"Breast Cancer Basic Clin Res"},{"key":"2109_CR36","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol Off J Eur Soc Med Oncol. 2020;31:1623\u201349.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2109_CR37","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, et al. Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110\u201322.","journal-title":"N Engl J Med"},{"key":"2109_CR38","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.ejca.2013.04.011","volume":"49","author":"M Campone","year":"2013","unstructured":"Campone M, et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer. 2013;49:2621\u201332.","journal-title":"Eur J Cancer"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02109-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02109-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02109-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:35:33Z","timestamp":1766572533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02109-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2109"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02109-3","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent. The Ethics Committees of all participating sites approved the study protocol before commencing study activities at the site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript and give their consent for its publication in\n                      Breast Cancer Research\n                      . Additionally, written informed consent for publication has been obtained from all participants involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}